Dyne Therapeutics (DYN)
(Real Time Quote from BATS)
$44.01 USD
+0.82 (1.90%)
Updated Jul 23, 2024 02:00 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
DYN 44.01 +0.82(1.90%)
Will DYN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for DYN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DYN
What Makes Dyne Therapeutics, Inc. (DYN) a Strong Momentum Stock: Buy Now?
Dyne Therapeutics (DYN) Is a Great Choice for 'Trend' Investors, Here's Why
DYN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dyne (DYN) Soars 28% on New Data From Muscle Disease Studies
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Other News for DYN
Buy Rating on Dyne Therapeutics Backed by Promising Clinical Data and Broad Therapeutic Potential of FORCE Platform
Dyne Therapeutics participates in a conference call with JPMorgan
Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease
Dyne announces new Pompe disease data showing potential of FORCE platform
Dynagreen Environmental Unveils New Board Structure